1832 Asset Management’s Lipocine LPCN Stock Holding History

1832 Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-418	Closed	-$11K	–	707
2018 Q1	$11K	Hold	418	–	–	﹤0.01%	601
2017 Q4	$24K	Hold	418	–	–	﹤0.01%	580
2017 Q3	$28K	Hold	418	–	–	﹤0.01%	592
2017 Q2	$29K	Hold	418	–	–	﹤0.01%	571
2017 Q1	$28K	Sell	418 -417	-50%	-$27K	﹤0.01%	618
2016 Q4	$52K	Buy	+835	New	+$52.9K	﹤0.01%	666

Other funds holding LPCN

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

1832 Asset Management's LPCN Position: Q2 2018 in Review

1832 Asset Management sold out of Lipocine (LPCN) in Q2 2018, closing a stake of 418 shares — an estimated $11K sold.

1832 Asset Management first reported a position in LPCN in Q4 2016 and held it in 6 quarters. The position peaked at $52K in Q4 2016. 30 funds tracked by Wall St. Rank hold LPCN as of Q2 2018.

1832 Asset Management reported no remaining Lipocine position as of Q2 2018 after selling out during the quarter.
1832 Asset Management sold 418 Lipocine shares in Q2 2018, an estimated $11K.
1832 Asset Management first reported a position in Lipocine in Q4 2016 and held it in 6 quarters.
1832 Asset Management's Lipocine position peaked at $52K in Q4 2016.
30 funds tracked by Wall St. Rank held Lipocine as of Q2 2018.

Based on 1832 Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.